Episode #28
In this episode of Living Heart Smart, Dr. Matt DeVane and Dr. Carolyn Lacey discuss the new cholesterol-lowering medication Inclisiran, its mechanism of action, and how it compares to traditional statins. They explore who might benefit from this medication, practical aspects of its administration, potential side effects, and the challenges of insurance coverage. The conversation emphasizes the importance of lowering LDL cholesterol for heart health and the evolving landscape of cardiovascular medications.
Takeaways
Inclisiran is a new medication that can replace daily statins.
It works by blocking the PCSK9 protein, enhancing LDL receptor function.
Patients with statin intolerance may benefit from Enclisarin.
The medication is administered twice a year, improving compliance.
Enclisarin can be used in conjunction with statins for better LDL control.
It has shown significant LDL reduction in clinical trials.
Side effects are minimal, primarily limited to injection site reactions.
Insurance coverage can be a barrier to accessing Enclisarin.
Lowering LDL cholesterol is crucial for reducing cardiovascular risk.
The future of cholesterol management may include more innovative therapies.
Chapters
00:00 Introduction to Inclisiran and Statins
02:15 Understanding Inclisiran Mechanism of Action
04:54 Comparing Inclisiran and Statins
07:33 Practical Applications and Patient Selection
10:18 Addressing Lipoprotein(a) and Inclisiran
12:53 Side Effects and Compliance Issues
15:28 Insurance and Cost Considerations
18:18 Conclusion and Future Directions